一项针对在医院布美诺龙项目中接受治疗的患者的回顾性病历审查研究。
A retrospective chart review study of patients treated in a hospital-based brexanolone program.
作者信息
Diaz Zobeida M, Howard Margaret M, Moreno Keyline V, Halwes Madilyn G, Battle Cynthia L
机构信息
Department of Psychiatry and Human Behavior, The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Division of Women's Behavioral Health, Department of Medicine, Women & Infants Hospital of Rhode Island, Care New England Health System, Providence, RI, USA.
出版信息
Arch Womens Ment Health. 2025 May 2. doi: 10.1007/s00737-025-01588-9.
PURPOSE
Postpartum depression (PPD), the most common childbirth complication in the United States, can be treated using brexanolone, an intravenous form of allopregnanolone.
METHODS
This retrospective chart review study evaluated clinical outcomes of 64 postpartum women who received brexanolone infusion for PPD in a real-world setting.
RESULTS
Treatment was associated with improved depression and anxiety symptoms, and 71% of patients reported significant improvement in their PPD.
CONCLUSIONS
While further research is needed, this study supports brexanolone as an efficacious treatment for PPD.
目的
产后抑郁症（PPD）是美国最常见的分娩并发症，可使用布雷沙诺龙（别孕烯醇酮的静脉注射形式）进行治疗。
方法
这项回顾性图表审查研究评估了64名在现实环境中因产后抑郁症接受布雷沙诺龙输注的产后女性的临床结果。
结果
治疗与抑郁和焦虑症状的改善相关，71%的患者报告其产后抑郁症有显著改善。
结论
虽然需要进一步研究，但本研究支持布雷沙诺龙作为产后抑郁症的有效治疗方法。
Zotero 插件